Meeting
2024 ASCO Annual Meeting
A phase II study of plerixafor combined with whole brain radiation therapy (WBRT) for patients with newly diagnosed glioblastoma.
Authors
Toni Cao
Stanford University, Palo Alto, CA
Toni Cao , Yuan Gu , Banu Yagmurlu , Hari Priya Yerraballa , Sophie Bertrand , Lewis Naya , Kate Miller , Michael Iv , Scott G. Soltys , Chirag B Patel , Seema Nagpal , Reena Parada Thomas , Martin Brown , Lawrence David Recht
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03746080
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2075)
DOI
10.1200/JCO.2024.42.16_suppl.2075
Abstract #
2075
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Association of SDF1 inhibition with local control and relative cerebral blood volume of glioblastoma.
First Author: Reena Parada Thomas
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi
Poster
2016 ASCO Annual Meeting
A phase I study of chemo-radiotherapy with plerixafor for newly diagnosed glioblastoma (GB).
First Author: Reena Parada Thomas